Diarrhea, in the context of human immunodeficiency virus (HIV) infection, is an enormously important clinical issue (Smith et al., 1988). Diarrhea in patients with AIDS is extremely problematic for both patient and clinician. More than 50% of AIDS patients suffer from diarrhea, the cause of which is unexplained in most of the cases. The causes of diarrhea in HIV infection are multifactorial. Chiefly, these may be caused by the primary retroviral infection per se, several opportunistic infections, alteration of gut microbiome, immune reconstitution, water sanitation or as a complication of highly active anti-retroviral therapy (HAART) like didanosine or ritonavir, and may also result from induced pancreatic insufficiency (Haas et al., 2011; Saha et al., 2011; Murray and Rubio-Tapia, 2012; Vyas et al., 2012; Agholi et al., 2013; Martin et al., 2013; Clay and Crutchley, 2014; Dye, 2014; Dikman et al., 2015; Green et al., 2015; Rubaihayo et al., 2015; Yates et al., 2015). The diarrhea in primary HIV infection is primarily secretory in nature (Juckett and Trivedi, 2011; MacArthur and DuPont, 2012). Some preliminary studies have suggested the role of viral proteins in causation and aggravation of diarrhea in HIV infected patients. For example, retroviral tat proteins have been demonstrated to enhance myenteric neuronal excitability by altering different sodium channels (Ngwainmbi et al., 2014). It is obvious that in HIV infection, a viral specific protein that affects genomic transcription would affect diverse cellular mechanism (s). This opinion piece advances a concept of how HIV may gain entry into the gastrointestinal mucosa using an upstream neuropeptide mechanism, providing a perspective of an incipient mechanism involved in mucosal disease caused by HIV and potential druggable targets for HIV induced diarrhea.
Namely, the hypothesis is based on two key reported observations: (i) the molecular overlap of a pentapeptide belonging to gp120, the key viral envelope protein that helps in cellular docking and a segment of vasoactive intestinal polypeptide (VIP) (Pert et al., 1988). HIV have been variously reported to bind to the VIP receptors, VPAC1 and VPAC2, and produce differential effects (see below). (ii) The earliest observations from HIV infected patients of the elevation of serum VIP during primary HIV illness and diarrhea (Manfredi et al., 1993, 1994). Potentially, how primary mucosal HIV infection causes elevation of serum VIP in not known. Here a rationale is presented that has striking similarity to a mechanism similar to Clostridium difficile diarrhea, one which involves disruption of cytoskeletome of mucosal epitheliocyte (Farrell and LaMont, 2000; Kumar et al., 2014). The tat proteins, through transcriptional activation, may hijack and alter the cytoskeletal machinery, thus resulting in leakage of cellular peptides like VIP (Vitale et al., 2013). This may also occur from submucosal neurons which are rich in VIP (Vitale et al., 2013). It is well known that excessive VIP in the mucosal extracellular space may cause secretory diarrhea (Krejs et al., 1980; Chambers et al., 2005), much like that seen in VIPoma (Krejs et al., 1977). There are only scant reports which have examined the electrolyte composition of diarrheal stool in HIV diarrhea or examined mucosal flux of electrolytes by Ussing's chamber after retroviral mucosal loading, but is generally agreed that it is of the secretory type (Schiller et al., 1994; Stockmann et al., 2000; Nwachukwu and Okebe, 2008).
The initial rise in VIP secretion may be related to a beneficial microenvironment of immune resistance. VIP have been reported to reduce viral production in HIV-1-infected human primary macrophages (Souza et al., 2014). The exact mechanisms of transfer of HIV-1 into gut mucosal and nerve terminals is not precisely known. Importantly, HIV-1 does not replicate in neurons and its productive infection in other cell types leads to the release of neurotoxic viral proteins, such as Tat, Nef, Vpr, and gp120 (Souza et al., 2014). These peptides may cause neuronal apoptosis. These neuroplastic aspects affecting the enteric nervous system (ENS) merits further studies. VIP exerts anti-inflammatory activity by inhibiting the activity or production of the interleukins IL-12, IL-6, IL-1β, tumor necrosis factor (TNF-α) and macrophage migration inhibitory factor, and stimulate the production of anti-inflammatory factors like IL-4 and IL-10. VIP and PACAP also participate in Th2 cell differentiation and inhibit synthesis of the Th1 cytokines IFN-γ and IL-2 (Souza et al., 2014). Additionally, VIP induces tolerance development in dendritic cells, induces the differentiation of T regulatory cells (Tregs) and reduces TLR2 and TLR4 expression on CD4+T cells (Chorny et al., 2006; Delgado and Ganea, 2013). It is known that viral antigen-induced cell death (AICD) is mediated by the T cell receptor (TCR) and involves Fas/Fas ligand (FasL) interactions. By affecting the expression of FasL. VIP may play significant role in the inhibition of FasL-mediated T cell cytotoxicity (Delgado and Ganea, 2000) and potentially alter the course of primary mucosal HIV infection. An important area of investigations would be how the intraepithelial lymphocytes and dendritic cells fail to mount adequate antiviral response after the initial infections and the role of CD25-FoxP+ve Treg cells (Wang et al., 2015).
The small homology (five amino acids) between VIP peptide sequences and the variable region V2 of HIV-1 gp120 (Sacerdote et al., 1987) suggest that VIP and their receptors might potentially participate in the pathogenesis of AIDS. These initial suggestive hypothesis came during exploration of possible mechanisms of neurocognitive complications that arose in the HIV infected populations (before the era of HAART) (Ngwainmbi et al., 2014). It has been proposed that VIP could block HIV-1 entry into target cells through direct interaction with the CD4 molecule (Souza et al., 2014). VIP also could act as a blocking peptide by binding to gp120, and prevent HIV binding to target cells. Additionally, these peptides may modulate transfer of HIV from macrophages/dendritic cells to mucosal epitheliocyte and submucosal neurons. These aspects merits systematic testing.
VIP receptor activation by HIV-1 produces opposing effects. It has been reported that productive HIV-1 infection can be facilitated by the sole activation of VPAC1, one of the major receptor classes for VIP (Bokaei et al., 2007). On the other hand, viral production is reduced in HIV-1-infected cells either following the engagement of VPAC2, the other major receptor for VIP (Branch et al., 2002). However, when cells are treated with VIP, with resultant engagement of both VPAC1 and VPAC2, HIV-1 production is reduced in the target cells (Temerozo et al., 2013). An initial pilot study could not detect the effect of VIP receptors (Nguyen, 1988). The precise mechanism for this disconcordant observation is not known but may have resulted from lack of examination of the multitude of splice variants of VIP receptors (Bokaei et al., 2006) and differential selectivity of peptide fragments and full-length VIP sequence on binding affinity to its receptors (Rorstad et al., 1990).
If mucosal ulcer occurs with HIV infections and viral entry is not well known. In other organs, HIV is known to cause epitheliocyte damage. For example, HIV associated nephropathy (HIVAN) is associated with collapsing glomerulitis (Rosenberg et al., 2015). This epithelial damage is known to be associated with alteration of transcription factors like snail (Kumar et al., 2011). Snail regulates the genomic expression of different kinds of myosin by acting on its promoter (Chaudhury et al., 2014). Whether HIV alters myosin promoter expression and functions after retroviral genome integration merits further investigation.
Additional hypotheses have been posited about HIV mucosal disease. Preliminary suggestions have been made about morphine based mechanisms of HIV mucosal illness, based on empiric observations of worsening HIV primary disease in opioid abusers (Samikkannu et al., 2015; Sindberg et al., 2015; Weisberg et al., 2015). This correlation may not be necessarily be mechanistic, as morphine based mechanism in general inhibit oro-aboral transit of luminal contents and anti-diarrheal in its summative pharmacologic manifestations. Furthermore, apart from opioid abuse, injection drug use may produce a number of confounding situations in HIV infected people including hepatitis C virus (HCV) coinfections. A common route of HIV entry, apart from being in circulation, are sexual practices like anal penetration exercised by preferences like men having sex with men (MSM) (Wahome et al., 2013). Whether such acts cause mucosal entry and acts as a nidus for HIV entry and how VIP contributes to these process merits further exploration. HIV infected populations are exposed to the risk of multiple sexually-transmitted infections (STI), including syphilis (Jia et al., 2015; Taylor et al., 2015), and which is prevalent in epidemic proportions across the globe. Syphilis may cause Crohn's like colitis-type proctitis (Davis and Goldstone, 2009; Lamb et al., 2013), especially with prevalent sexual practices, and these mucosal lesions may also favor HIV dissemination through the inflamed mucosa.
The first-in-class agent crofelemer has been recently FDA (US Food and Drug Administration) approved to manage HIV and HAART- induced non-infectious diarrhea (Crutchley et al., 2010). Crofelemer derived from extract of Croton lechleri (dragon's blood, Sangre de Drago/Sangre de Grado) blocks the chloride channels CFTR and TMEM16A. This is an end point mechanism for inhibiting chloride secretion-induced water drag and resulting secretory diarrhea. VIP in the extracellular space may be related to creating an antiviral environment, but at the cost of inducing secretory diarrhea, which upon chronic persistence may often be fatal and contribute to marked cachexia. Some recent hypotheses have suggested the plausible role of ENS-stimulated VIP release and its protective effects on intestinal epithelial barrier (Ben-Horin and Chowers, 2008). HIV has also been proposed to cause non-malabsorptive diarrhea by affecting leak flux mechanism in a small series of duodenal biopsies (Stockmann et al., 1998). The effect of HIV infection on barrier function is an important area of future investigation. If the VIP receptor mechanisms for HIV viral entry into the gastrointestinal mucosa are further validated, blocking the pentapeptide by heteroclitic peptide or a blocking antibody could become a simple but potent vaccine strategy to prevent HIV diarrhea and control persistence and spread of the retrovirus.
In summary, HIV associated diarrhea remains a major cause of morbidity and mortality even now, with presentations comparable to the earliest report of “slim disease”, the cachectic manifestation, from rural Uganda (Serwadda et al., 1985). Public health measures and reductionistic bench side approaches are needed for appropriate rationale management of this global pandemic of HIV- associated diarrhea.
Statements
Acknowledgments
The author wishes to thank his mentor Dr. Naveen Patil for inspiration.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AgholiM.HatamG. R.MotazedianM. H. (2013). HIV/AIDS-associated opportunistic protozoal diarrhea. AIDS Res. Hum. Retroviruses29, 35–41. 10.1089/aid.2012.0119
2
Ben-HorinS.ChowersY. (2008). Neuroimmunology of the gut: physiology, pathology, and pharmacology. Curr. Opin. Pharmacol.8, 490–495. 10.1016/j.coph.2008.07.010
3
BokaeiP. B.MaX. Z.ByczynskiB.KellerJ.SakacD.FahimS.et al. (2006). Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors. Genomics88, 791–800. 10.1016/j.ygeno.2006.07.008
4
BokaeiP. B.MaX. Z.SakacD.BranchD. R. (2007). HIV-1 integration is inhibited by stimulation of the VPAC2 neuroendocrine receptor. Virology362, 38–49. 10.1016/j.virol.2006.12.012
5
BranchD. R.ValentaL. J.YousefiS.SakacD.SinglaR.BaliM. Z.et al. (2002). VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively facilitates productive HIV-1 infection. AIDS16, 309–319. 10.1097/00002030-200202150-00001
6
ChambersJ. D.BornsteinJ. C.SjövallH.ThomasE. A. (2005). Recurrent networks of submucous neurons controlling intestinal secretion: a modeling study. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G887–G896. 10.1152/ajpgi.00491.2004
7
ChaudhuryA.De Miranda-NetoM. H.PereiraR. V.ZanoniJ. N. (2014). Myosin Va but Not nNOSα is Significantly Reduced in Jejunal Musculomotor Nerve Terminals in Diabetes Mellitus. Front. Med. (Lausanne)1:17. 10.3389/fmed.2014.00017
8
ChornyA.Gonzalez-ReyE.GaneaD.DelgadoM. (2006). Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. Ann. N.Y. Acad. Sci. 1070, 190–195. 10.1196/annals.1317.011
9
ClayP. G.CrutchleyR. D. (2014). Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. Infect. Dis. Ther. 3, 103–122. 10.1007/s40121-014-0047-5
10
CrutchleyR. D.MillerJ.GareyK. W. (2010). Crofelemer, a novel agent for treatment of secretory diarrhea. Ann. Pharmacother. 44, 878–884. 10.1345/aph.1M658
11
DavisT. W.GoldstoneS. E. (2009). Sexually transmitted infections as a cause of proctitis in men who have sex with men. Dis. Colon Rectum. 52, 507–512. 10.1007/DCR.0b013e31819ad537
12
DelgadoM.GaneaD. (2000). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. J. Immunol. 164, 1200–1210. 10.4049/jimmunol.164.3.1200
13
DelgadoM.GaneaD. (2013). Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids45, 25–39. 10.1007/s00726-011-1184-8
14
DikmanA. E.SchonfeldE.SrisarajivakulN. C.PolesM. A. (2015). Human Immunodeficiency virus-associated Diarrhea: still an issue in the era of antiretroviral therapy. Dig. Dis. Sci.60, 2236–2245. 10.1007/s10620-015-3615-y
15
DyeC. (2014). After 2015: infectious diseases in a new era of health and development. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 369:20130426. 10.1098/rstb.2013.0426
16
FarrellR. J.LaMontJ. T. (2000). Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. Curr. Top. Microbiol. Immunol. 250, 109–125. 10.1007/978-3-662-06272-2_6
17
GreenE. K.AmbroseL. R.WebsterD. P.AtkinsonC.GriffithsP.MurrayC. D.et al. (2015). Intractable diarrhoea despite immune reconstitution in an HIV positive man. J. Clin. Virol.69, 219–222. 10.1016/j.jcv.2015.04.008
18
HaasA.ZimmermannK.GrawF.SlackE.RusertP.LedergerberB.et al. (2011). Oxenius A; SwissHIV Cohort Study. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut60, 1506–1519. 10.1136/gut.2010.224774
19
JiaZ.HuangX.WuH.ZhangT.LiN.DingP.et al. (2015). HIV burden in men who have sex with men: a prospective cohort study 2007-2012. Sci. Rep.5, 11205. 10.1038/srep11205
20
JuckettG.TrivediR. (2011). Evaluation of chronic diarrhea. Am. Fam. Physician. 84, 1119–1126.
21
KrejsG. J.FordtranJ. S.FahrenkrugJ.Schaffalitzky de MuckadellO. B.FischerJ. E.HumphreyC. S.et al. (1980). Effect of VIP infusion in water and ion transport in the human jejunum. Gastroenterology78, 722–727.
22
KrejsG. J.WalshJ. H.MorawskiS. G.FordtranJ. S. (1977). Intractable diarrhea. Intestinal perfusion studies and plasma VIP concentrations in patients with pancreatic cholera syndrome and surreptitious ingestion of laxatives and diuretics. Am. J. Dig. Dis. 22, 280–292. 10.1007/BF01072184
23
KumarD.SalhanD.MagoonS.TorriD. D.SayeneniS.SagarA.et al. (2011). Adverse host factors exacerbate occult HIV- associated nephropathy. Am. J. Pathol. 179, 1681–1692. 10.1016/j.ajpath.2011.06.013
24
KumarN.EkkaM. P. R.RanjanS.SinhaS.SharmaS. K.ChaudhryR.et al. (2014). Clostridium difficile infections in HIV-positive patients with diarrhoea. Natl. Med. J. India27, 138–140.
25
LambC. A.LambE. I.MansfieldJ. C.SankarK. N. (2013). Sexually transmitted infections manifesting as proctitis. Frontline Gastroenterol. 4, 32–40. 10.1136/flgastro-2012-100274
26
MacArthurR. D.DuPontH. L. (2012). Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin. Infect. Dis.55, 860–867. 10.1093/cid/cis544
27
ManfrediR.VezzadiniP.CostigliolaP.RicchiE.FantiM. P.ChiodoF. (1993). Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea. Effects of treatment with octreotide. AIDS7, 223–226. 10.1097/00002030-199302000-00010
28
ManfrediR.VezzadiniP.FantiM. P.ChiodoF. (1994). Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex (ARC). Scand. J. Infect. Dis. 26, 55–57. 10.3109/00365549409008591
29
MartinT. C.ScourfieldA.RockwoodN.MartinN. K.PatelN.NelsonM.et al. (2013). Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned. HIV Med.14, 161–166. 10.1111/j.1468-1293.2012.01047.x
30
MurrayJ. A.Rubio-TapiaA. (2012). Diarrhoea due to small bowel diseases. Best Pract. Res. Clin. Gastroenterol. 26, 581–600. 10.1016/j.bpg.2012.11.013
31
NguyenT. D. (1988). Peptide T from human immunodeficiency virus envelope does not interact with hepatic, intestinal and colonic vasoactive intestinal peptide (VIP) receptors. Peptides9, 425–428. 10.1016/0196-9781(88)90279-3
32
NgwainmbiJ.DeD. D.SmithT. H.El-HageN.FittingS.KangM.et al. (2014). Effects of HIV-1 Tat on enteric neuropathogenesis. J. Neurosci.34, 14243–14251. 10.1523/JNEUROSCI.2283-14.2014
33
NwachukwuC. E.OkebeJ. U. (2008). Antimotility agents for chronic diarrhoea in people with HIV/AIDS. Cochrane Database Syst Rev. 4:CD005644. 10.1002/14651858.cd005644.pub2
34
PertC. B.RuffM. R.HillJ. M. (1988). AIDS as a neuropeptide disorder: peptide T, VIP, and the HIV receptor. Psychopharmacol. Bull. 24, 315–319.
35
RorstadO. P.WankeI.CoyD. H.FournierA.HuangM. (1990). Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide. Mol. Pharmacol.37, 971–977.
36
RosenbergA. Z.NaickerS.WinklerC. A.KoppJ. B. (2015). HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat. Rev. Nephrol. 11, 150–160. 10.1038/nrneph.2015.9
37
RubaihayoJ.TumwesigyeN. M.Konde-LuleJ. (2015). Trends in prevalence of diarrhoea, Kaposi's sarcoma, bacterial pneumonia, malaria and geohelminths among HIV positive individuals in Uganda. AIDS Res. Ther.12:20. 10.1186/s12981-015-0060-0
38
SacerdoteP.RuffM. R.PertC. B. (1987). Vasoactive intestinal peptide 1-12: a ligand for the CD4 (T4)/human immunodeficiency virus receptor. J. Neurosci. Res. 18, 102–107. 10.1002/jnr.490180117
39
SahaK.FirdausR.SantraP.PalJ.RoyA.BhattacharyaM. K.et al. (2011). Recent pattern of Co-infection amongst HIV seropositive individuals in tertiary care hospital, Kolkata. Virol. J. 8:116. 10.1186/1743-422X-8-116
40
SamikkannuT.RanjithD.RaoK. V.AtluriV. S.PimentelE.El-HageN.et al. (2015). HIV-1 gp120 and morphine induced oxidative stress: role in cell cycle regulation. Front. Microbiol.6:614. 10.3389/fmicb.2015.00614
41
SchillerL. R.RiveraL. M.SantangeloW. C.LittleK. H.FordtranJ. S. (1994). Diagnostic value of fasting plasma peptide concentrations in patients with chronic diarrhea. Dig. Dis. Sci. 39, 2216–2222. 10.1007/BF02090374
42
SerwaddaD.MugerwaR. D.SewankamboN. K.LwegabaA.CarswellJ. W.KiryaG. B.et al. (1985). Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet2, 849–852. 10.1016/S0140-6736(85)90122-9
43
SindbergG. M.SharmaU.BanerjeeS.AnandV.DuttaR.GuC. J.et al. (2015). An infectious murine model for studying the systemic effects of opioids on early HIV pathogenesis in the gut. J. Neuroimmune Pharmacol.10, 74–87. 10.1007/s11481-014-9574-9
44
SmithP. D.LaneH. C.GillV. J.ManischewitzJ. F.QuinnanG. V.FauciA. S.et al. (1988). Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann. Intern. Med. 108, 328–333. 10.7326/0003-4819-108-3-328
45
SouzaT. M.TemerozoJ. R.Giestal-de-AraujoE.Bou-HabibD. C. (2014). The effects of neurotrophins and the neuropeptides VIP and PACAP on HIV-1 infection: histories with opposite ends. Neuroimmunomodulation21, 268–282. 10.1159/000357434
46
StockmannM.FrommM.SchmitzH.SchmidtW.RieckenE. O.SchulzkeJ. D. (1998). Duodenal biopsies of HIV-infected patients with diarrhoea exhibit epithelial barrier defects but no active secretion. AIDS12, 43–51. 10.1097/00002030-199801000-00006
47
StockmannM.SchmitzH.FrommM.SchmidtW.PauliG.ScholzP.et al. (2000). Mechanisms of epithelial barrier impairment in HIV infection. Ann. N. Y. Acad. Sci.915, 293–303. 10.1111/j.1749-6632.2000.tb05257.x
48
TaylorM. M.NewmanD. R.SchillingerJ. A.LewisF. M.FurnessB.BraunsteinS.et al. (2015). Viral Loads among HIV- Infected Persons Diagnosed with Primary and Secondary Syphilis in Four US Cities. New York City, NY; Philadelphia, PA; Washington, DC; Phoenix: A. Z. J Acquir Immune Defic Syndr.
49
TemerozoJ. R.JoaquimR.RegisE. G.SavinoW.Bou-HabibD. C. (2013). Macrophage resistance to HIV-1 infection is enhanced by the neuropeptides VIP and PACAP. PLoS ONE8:e67701. 10.1371/journal.pone.0067701
50
VitaleN.BeaumelleB.BaderM. F.Tryoen-TóthP. (2013). HIV-1 Tat protein perturbs diacylglycerol production at the plasma membrane of neurosecretory cells during exocytosis. Commun. Integr. Biol.6:e25145. 10.4161/cib.25145
51
VyasN.PathanN.AzizA. (2012). Enteric pathogens in HIV-positive patients with diarrhoea and their correlation with CD4+ T-lymphocyte counts. Trop. Parasitol.2, 29–34. 10.4103/2229-5070.97236
52
WahomeE.FeganG.OkukuH. S.MugoP.PriceM. A.MwashigadiG.et al. (2013). Evaluation of an empiric risk screening score to identify acute and early HIV-1 infection among MSM in Coastal Kenya. AIDS27, 2163–2166. 10.1097/QAD.0b013e3283629095
53
WangX.XuH.ShenC.AlvarezX.LiuD.PaharB.et al. (2015). Profound loss of intestinal Tregs in acutely SIV-infected neonatal macaques. J. Leukoc. Biol. 97, 391–400. 10.1189/jlb.4A0514-266RR
54
WeisbergD. F.GordonK. S.BarryD. T.BeckerW. C.CrystalS.EdelmanE. J.et al. (2015). Long-term prescription of opioids and/or benzodiazepines and mortality among HIV-infected and uninfected patients. J. Acquir. Immune Defic. Syndr. 69, 223–233. 10.1097/QAI.0000000000000591
55
YatesT.LantagneD.MintzE.QuickR. (2015). The impact of water, sanitation, and hygiene interventions on the health and well-being of people living with HIV: a systematic review. J. Acquir. Immune Defic. Syndr. 68, S318–S330. 10.1097/QAI.0000000000000487
Summary
Keywords
AIDS, chronic diarrhea, vaccine, neuropeptide, Treg, macrophage
Citation
Chaudhury A (2015) VIP in HIV Diarrhea: Finding Links for the “Slim Disease”. Front. Physiol. 6:402. doi: 10.3389/fphys.2015.00402
Received
16 October 2015
Accepted
07 December 2015
Published
23 December 2015
Volume
6 - 2015
Edited by
Ghanshyam Upadhyay, City College of New York-CUNY, USA
Reviewed by
Sandeep Kumar, State University of New York College of Optometry, USA; Ravi C. Kalathur, New York Structural Biology Center, USA
Updates
Copyright
© 2015 Chaudhury.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Arun Chaudhury arunchaudhury.boston@gmail.com; arun.chaudhury@adh.org
This article was submitted to Gastrointestinal Sciences, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.